Have i missed something, so they have already started human trials which is very good news, mind i must have missed the ann.
Excert from RH annual report.
second drug development program has already entered human trials and results in patients with Optic Atrophy are also imminent – expected before the end of this year. The Polycystic Kidney Disease program is following shortly behind and is expected to enter human trials within the next 6 months
Very impressive Annual report, could this be the perfect storm with bio techs looking to be slowly coming back into favour and so much promise with all that PYC have in the pipeline.
GLTA
PYC Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)